FT
FLXN

Fiduciary Trust’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Fiduciary Trust’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,000
Closed -$101K – 520
2017
Q2 		$101K Buy
+5,000
New +$104K ﹤0.01% 533

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Fiduciary Trust's FLXN Position: Q3 2017 in Review

Fiduciary Trust sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2017, closing a stake of 5,000 shares — an estimated $101K sold.

Fiduciary Trust first reported a position in FLXN in Q2 2017 and held it in 1 quarter. The position peaked at $101K in Q2 2017. 116 funds tracked by Wall St. Rank hold FLXN as of Q3 2017.

  • Fiduciary Trust reported no remaining Flexion Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Fiduciary Trust sold 5,000 Flexion Therapeutics, Inc. shares in Q3 2017, an estimated $101K.
  • Fiduciary Trust first reported a position in Flexion Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Fiduciary Trust's Flexion Therapeutics, Inc. position peaked at $101K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2017.

Based on Fiduciary Trust's 13F filing for Q3 2017, filed 2 Nov 2017.